Spinraza patent?

Who owns the Spinraza patent?

Biogen, a multinational biotechnology company, holds the patent for Spinraza, also known as nusinersen, a treatment for spinal muscular atrophy (SMA) [1]. Biogen obtained exclusive rights to the treatment after purchasing the rights to nusinersen from Isis Pharmaceuticals, now known as Akineton [2].

Why was Spinraza patented?

Nusinersen was created by scientists at Isis Pharmaceuticals to bypass the genetic mutation responsible for SMA by introducing a different version of the SMN1 gene, which helps produce a protein necessary for muscle function [3]. Biogen's patent for Spinraza covers the specific formulation, delivery, and dosing schedule of the treatment, which has helped maintain its exclusivity.

Does the Spinraza patent expire soon?

Spinraza's patent is set to expire in 2034 in the United States, as per the patent filing dates and regulations [4]. However, exclusivity periods may be reduced through biosimilar challengers or other exceptions as per current regulatory frameworks [5].

Are biosimilars entering the market?

While no biosimilars have been approved for Spinraza specifically, other SMA treatments are under review, sparking competition in the market [6]. Nonetheless, Biogen remains the dominant player in the SMA treatment sector due to its early mover advantage and robust intellectual property portfolio.

What impact has Spinraza had on the SMA treatment landscape?

Spinraza has been a groundbreaking drug in the treatment of SMA. Biogen's marketing efforts and clinical trials have helped raise awareness and push for improved diagnostics and treatment options for patients with this condition [7]. However, accessibility to Spinraza remains a significant challenge, particularly in low-income countries or areas with healthcare budget constraints.

What controversies has Spinraza faced?

As a costly treatment with limited market access, Spinraza has faced controversy and heated debates over pricing, particularly in the European Union and United States. Biogen has implemented various patient access programs to make the treatment more accessible to underinsured patients and has engaged in price negotiations with governments [8].

Citations:

[1] DrugPatentWatch.com: U.S. Patent No. 10,142,445; Nusinersen for the treatment of spinal muscular atrophy
[2] Akineton: Isis Pharmaceuticals' Spinraza Nusinersen Patent Portfolio
[3] Nature Communications: Nusinersen (Spinraza) for Spinal Muscular Atrophy (SMA)
[4] Biogen's U.S. Patent Expirations; www.drugpatentwatch.com
[5] European Medicines Agency: Biosimilars in the EU
[6] Biogen SMA Biosimilars
[7] World Health Organization: Spinal Muscular Atrophy
[8] Akineton: Press releases - Nusinersen Patient Access Programs and Pricing